glp-1 black box warning Before you panic about the “black warning,” read this. As an endocrinologist, I see too many thyroid patients scared away from medications because of misinformation. Let's simplify it: • Hashimoto's? GIP/GLP-1 | Vumedi

Taken together, the unique characteristics of MSNs, such as high drug loading capacity, excellent biocompatibility, surface modifiability for targeted delivery, multifunctional therapeutic potential, and enhanced BBB penetration, make them highly promising nanocarriers for glioblastoma therapy, offering distinct advantages over other delivery systems such as liposomes and polymeric nanoparticles

Davani-Davari D, Negahdaripour M, Karimzadeh I, et al

Regulatory agencies have not issued warnings linking these medications to dementia or Alzheimers disease, and the current body of evidence does not establish that they increase cognitive risk

The project is funded by a $210,000 investment from NDSU, Sanford Health and the North Dakota Department of Health and Human Services and is designed to foster collaboration among research scientists with diverse expertise and backgrounds across both organizations